IRVINE, Calif.—December 4, 2023—Aureka Biotechnologies today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

Aureka Biotechnologies is at the forefront of AI-driven drug discovery, pioneering the integration of vast multimodal pharmaceutical datasets with advanced generative AI models. Specializing in the design and optimization of innovative immunotherapies, the company leverages structure-aware computational techniques to identify and develop novel therapeutics. Its data-driven approach is setting new standards for rapid, precise, and effective drug discovery.

Joining NVIDIA Inception will allow Aureka Biotechnologies to scale its AI-driven drug discovery efforts through access to advanced NVIDIA hardware and software, deep learning tools, and industry expertise. The program will also offer Aureka Biotechnologies the opportunity to collaborate with industry-leading experts and other AI-driven organizations.

“Our participation in NVIDIA Inception represents a pivotal step in our mission to transform drug discovery,” said Dr. Weian Zhao, CEO of Aureka Biotechnologies. “The computational power and support provided by the program will significantly enhance our ability to bring innovative treatments to market faster and more efficiently.”

NVIDIA Inception helps startups during critical stages of product development, prototyping, and deployment. Every NVIDIA Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.

About Aureka Biotechnologies

Aureka Biotechnologies is a premier biotech startup committed to democratizing the pharmaceutical industry to defeat disease. Aureka is developing a best-in-class therapeutic discovery platform that uniquely integrates high-throughput, single-cell-based functional screening, synthetic biology-based autonomous discovery, and generative AI-based therapeutic design and multi-objective optimization. Empowered by large-scale, multi-metric data generated at an unprecedented scale and rapid reinforcement learning, Aureka’s AI solutions can uncover therapeutic design principles and exponentially accelerate the discovery of a wide range of macromolecule and immunotherapeutic modalities including bispecific antibodies, ADCs, TCR-T, polypeptides, enzymes, as well as new therapeutics for previously challenging targets and mechanisms such as GPCR.

#nvidiainception #AurekaBio #Innovation #Biotechnology #AI #DataScience #HealthcareInnovation #StartupGrowth #BreakingNews